R(+) Zileuton Program

We are currently pursuing development of the R isomer of zileuton. We have obtained preclinical data that shows a single enantiomer of zileuton possesses higher potency for 5-lipoxygenase inhibition and clinical data after dosing of the racemate that demonstrates this enantiomer exhibits a more prolonged plasma pharmacokinetic exposure profile. We believe that these features may offer the opportunity for us to develop a product candidate with a reduced tablet size or less frequent dose administration. In 2007, we plan to continue to evaluate this enantiomer to establish its pharmacokinetic and 5-lipoxygenase inhibitory profiles. The successful development of the R isomer could lead to an enhanced intellectual property position of zileuton, which could enable us to examine the potential development of a new zileuton tablet product candidate for the treatment of asthma and other indications including, but not limited to, Chronic Obstructive Pulmonary Disease (COPD), atherosclerosis and nasal polyps.

Home | About | Products | Development Pipeline | News | Investors | Careers

For Terms of Use and Disclaimer, click here. For Privacy Policy, click here.
This site is intended for residents of the United States, Puerto Rico and U.S. territories.

© 2008 Cornerstone Therapeutics Inc., Cary, NC. All rights reserved.
Unless otherwise specified, all product names in this Internet site are trademarks owned by or licensed to Cornerstone Therapeutics Inc., its subsidiaries or affiliates. Use of any Cornerstone Therapeutics trademark, trade name or trade dress in this site without the prior written authorization of Cornerstone Therapeutics Inc., except to identify the product of the company, is strictly prohibited.